Working… Menu

Safety of VAX102 Vaccine Given With Seasonal Flu Vaccine in Healthy Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00921973
Recruitment Status : Completed
First Posted : June 17, 2009
Last Update Posted : September 23, 2014
Information provided by (Responsible Party):
VaxInnate Corporation

Brief Summary:
The study will assess the safety, reactogenicity, and tolerability of VAX102 when given with Trivalent Inactivated Influenza Vaccine (TIV) delivered in the same arm as two separate IM injections in healthy adults 18 to 49 years. The investigators will measure the immunogenicity of the VAX102 when given with TIV and the antibody response to TIV when given with VAX102 compared to TIV alone.

Condition or disease Intervention/treatment Phase
Influenza Biological: VAX102 Biological: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Multicenter, Double-Blinded, Randomized, Placebo Controlled Study to Investigate the Safety and Immunogenicity of VAX102 When Given in the Same Arm With the Standard Influenza Vaccine in Healthy Adults
Study Start Date : June 2009
Actual Primary Completion Date : July 2009
Actual Study Completion Date : September 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot

Arm Intervention/treatment
Active Comparator: VAX102
Simultaneous administration of VAX102 1 ug i.m. plus TIV
Biological: VAX102
All subjects receive TIV, one half of the subjects are randomized to receive VAX102 1 ug and one half are randomized to receive placebo
Other Name: Universal influenza vaccine

Placebo Comparator: Placebo Biological: Placebo
All subjects receive TIV, one half of the subjects are randomized to receive VAX102 1 ug and one half are randomized to receive placebo

Primary Outcome Measures :
  1. Immune response [ Time Frame: 2 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 49 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male or female aged 18 - 49 years inclusive
  • Give written informed consent to participate in the study and adherence to all protocol requirements.
  • Healthy, as determined by medical history, physical examination, vital signs, and clinical safety laboratory examinations
  • Females willing to practice birth control during the study.
  • Women of childbearing potential must have a negative urine pregnancy test within 24 hours preceding receipt of vaccination.
  • Comprehension of the study requirements, expressed availability for the required study period, and ability to attend scheduled visits.
  • Did not receive influenza vaccination (TIV) during the 2008-2009 influenza season.

Exclusion Criteria:

  • Presence of significant acute or chronic, uncontrolled medical or psychiatric illness (institution of new medical or surgical treatment, or a significant dose alteration for uncontrolled symptoms or drug toxicity within 3 months) as determined by medical history and/or physical exam.
  • History of cancer.
  • History of impaired immunoresponsiveness, including diabetes.
  • Known hypersensitivity to a previous dose of influenza vaccine or allergy to eggs or any components of the study vaccines.
  • Received influenza vaccination during the 2008-2009 season
  • History of systemic hypersensitivity reactions to egg proteins, or any other component of FLUVIRIN®, or life-threatening reactions to previous influenza vaccinations.
  • Has known history of Guillain-Barré Syndrome
  • Presently receiving or history of receiving any medications or treatments that affects the immune system such as allergy shots, immune globulin, interferon, immunomodulators, cytotoxic drugs or drugs known to be frequently associated with significant major organ toxicity, or systemic corticosteroids (oral or injectable) in the past 6 months. Inhaled and topical corticosteroids will be allowed.
  • Participated in a clinical trial or received or planned administration of an investigational compound within 30 days before receiving study vaccine and/or during the study through the Day 28 evaluation.
  • Was vaccinated with a registered vaccine within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to receiving the study vaccine.
  • History of anaphylactic type reaction to injected vaccines.
  • History of drug or chemical abuse in the year before the study.
  • Use of new prescription medications started within 7 days before study entry.
  • Receipt of any blood products, including immunoglobulin, within 6 months before administration of study vaccine or anticipated receipt during the study period.
  • Donation of blood or blood products within 8 weeks before study entry or at any time during the study.
  • Has clinical signs of active infection and/or oral temperature of ≥ 38 (100.4 ºF). Study entry may be deferred for such individuals at the discretion of the investigator.
  • Has evidence or history of (within the previous 12 months) drug or alcohol abuse.
  • Any condition that, in the opinion of the investigator, might interfere with study objectives.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00921973

Layout table for location information
United States, Kansas
Johnson County Clin Trials
Lenexa, Kansas, United States, 66219
United States, Tennessee
Vanderbilt Clinical Trials Center
Nashville, Tennessee, United States, 37212
Sponsors and Collaborators
VaxInnate Corporation
Layout table for investigator information
Study Director: David N Taylor, MD VaxInnate Corporation

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: VaxInnate Corporation Identifier: NCT00921973     History of Changes
Other Study ID Numbers: VAX102-07
First Posted: June 17, 2009    Key Record Dates
Last Update Posted: September 23, 2014
Last Verified: September 2014
Keywords provided by VaxInnate Corporation:
universal influenza vaccine
Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Immunologic Factors
Physiological Effects of Drugs